Substrate inhibition level phosphorylation

Figure 6-1. The steps of glycolysis. Feedback inhibition of glucose phosphorylation by hexokinase, inhibition of pyruvate kinase, and the main regulatory, rate-limiting step catalyzed by phosphofructoki-nase (PFK-I) are indicated, pyruvate formation and substrate-level phosphorylation are the main outcomes of these reactions. Regeneration of NAD occurs by reduction of pyruvate to lactate during anaerobic glycolysis.

Random mechanisms wiU not show substrate inhibition of exchanges unless the levels of reactants that can form an abortive complex are varied together. The relative rates of the two exchanges will show whether catalysis is totally rate limiting (a rapid equilibrium random mechanism), or whether release of a reactant is slower. For kinases that phosphorylate sugars, the usual pattern is for sugar release to be partly rate limiting, but for nucleotides to dissociate rapidly (15, 16). 

The breakdown of succinyl coenzyme A may also be linked to the phosphorylation of GDP and IDP to yield GTP and ITP in the presence of inorganic phosphate. The enzyme catalyzing that reaction has been named the phosphorylating enzyme, and has been prepared in a crude form from heart muscle. This preparation also contains another enzyme, nucleoside diphosphate kinase, which catalyzes the transfer of phosphorus from GTP or ITP to ADP to yield ATP. The phosphorylation of ADP coupled to the oxidation of a-ketoglutarate is the only substrate level phosphorylation in the Krebs cycle, and, as can be expected, it is not inhibited by dinitrophenol. When O-labeled phosphate is used in the reaction, the label appears... 

Lower half The situation when the intramitochondrial NADH cannot be oxidized because of respiratory chain inhibition or anoxia. Substrate oxidation keeps NAD+ reduced (State 5 Chance and Williams, 1956). Inner membrane de novo fatty acid synthesis is turned on and reoxidizes intramitochondrial NADH, probably by reversal of the fatty acid oxidation assembly. The oxidized NAD, thereby made available, might permit some substrate-level phosphorylation. 

Pyruvate kinase, in general, is inhibited by high concentrations of ATP, alanine, acetyl-CoA and long-chain fatty acids. Thus the affinity of the enzyme for its substrate is lowered when energy requirements can be satisfied by other means. Conversely at low [ATP], the affinity of pyruvate kinase for phosphoenolpyruvate (PEP) increases to support the substrate-level phosphorylation of ADP even at low [PEP] because of its inherent instability. The liver isoenzyme is activated by fructose 1,6-bisphosphate so that pyruvate kinase activity is coordinated with variations in... 

AH 2/3 -dideoxynucleoside analogues are assumed to be intraceUularly phosphorylated to thek active form (5 -triphosphate), and then targeted at the vims-associated reverse transcriptase. The rate and extent of the 2 /3 -dideoxynucleosides phosphorylate to the 5 -triphosphates may be of equal or greater importance than the differences in the relative abiUties of these 5 -triphosphates to inhibit the vkal reverse transcriptase (171). At the level of vkal reverse transcriptase, the 5 -triphosphate of AZT and other dideoxynucleosides may either serve as a competitive inhibitor with respect to the natural substrates or may act as an alternate substrate, thus leading to chain termination (172). 

Pyruvate kinase possesses allosteric sites for numerous effectors. It is activated by AMP and fructose-1,6-bisphosphate and inhibited by ATP, acetyl-CoA, and alanine. (Note that alanine is the a-amino acid counterpart of the a-keto acid, pyruvate.) Furthermore, liver pyruvate kinase is regulated by covalent modification. Flormones such as glucagon activate a cAMP-dependent protein kinase, which transfers a phosphoryl group from ATP to the enzyme. The phos-phorylated form of pyruvate kinase is more strongly inhibited by ATP and alanine and has a higher for PEP, so that, in the presence of physiological levels of PEP, the enzyme is inactive. Then PEP is used as a substrate for glucose synthesis in the pathway (to be described in Chapter 23), instead... 

This can be illustrated by known interactions between the cAMP and Ca2+ pathways. A first messenger that initially activates the cAMP pathway would be expected to exert secondary effects on the Ca2+ pathway at many levels via phosphorylation by PKA. First, Ca2+ channels and the inositol trisphosphate (IP3) receptor will be phosphorylated by PKA to modulate intracellular concentrations of Ca2+. Second, phospholipase C (PLC) is a substrate for PKA, and its phosphorylation modulates intracellular calcium concentrations, via the generation of IP3) as well as the activity of PKC, via the generation of DAG, and several types of CAMK. Similarly, the Ca2+ pathway exerts potent effects on the cAMP pathway, for example, by activating or inhibiting the various forms of adenylyl cyclase expressed in mammalian tissues (see Ch. 21). 

The cAMP and Ca2+ pathways also interact at the level of protein kinases and protein phosphatases. This is illustrated by inhibitor-1 and DARPP-32, which are phosphorylated and activated by PKA and then inhibit PP1, which can dephosphorylate numerous substrates for Ca2+-dependent protein kinases. Another example is the physical association between PKA and PP2B (a Ca2+/ calmodulin-activated enzyme) via the AKAP-anchoring proteins. 

---